Restaurant Chain Cava Is ‘Positioned To Sustain Positive Transaction Growth,’ Analyst Says
Experience robust growth with CAVA Group Q1 revenue surges 30.3% YoY, surpassing estimates. Wedbush maintaining an Outperform rating.
ConocoPhillips’ Marathon Deal: Analyst Sees Short-Term Pain, Long-Term Gain
Analyst expects COP to have a negative reaction vs. its peers today. ConocoPhillips announced its plan for the acquisition of Marathon Oil. Can gain exposure through IEO and WEEI.
Volatility Spooks Investors As Treasury Yields, Dollar Climb Ahead Of Key Economic Releases: What’s Driving Markets Wednesday?
Volatility surged back into the market on Wednesday, with the CBOE Volatility Index (VIX) spiking 9% after hitting nearly three-year lows last week, fueled by fresh upticks in Treasury bond yields.
Johnson & Johnson’s Drug Seltorexant Aces Late-Stage Depression Trial
Johnson & Johnson reported successful Phase 3 trial results for seltorexant, an investigational treatment for major depressive disorder with insomnia.
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca’s Drug
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.
Shell And Exxon Eye North Sea Asset Sales In $500M Deal: Report
Shell and Exxon Mobil are nearing a $500 million deal to sell their jointly-owned gas fields in the North Sea to British producer Viaro Energy.
Time Runs Out For BHP Deal: $49-Billion Acquisition Of Anglo American Proves Too Complex To Solve
After weeks of discussions, BHP fails to acquire Anglo American due to concerns over the fate of South African assets.
What’s Going On With Blackstone Stock Today?
Blackstone to sell Turtle Bay Resort for $725 million, expected to close Q3 2024.
ConocoPhillips Acquires Marathon Oil In All-Stock Deal at 14.7% Premium: Details
Marathon Oil shares up 7.45% and ConocoPhillips shares down 3.56% after deal announcement for ConocoPhillips to acquire Marathon Oil for $22.5 billion in all-stock transaction.
Why Is AstraZeneca Stock Trading Lower On Tuesday?
AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.